Sorrento Therapeutics Inc

NASDAQ:SRNE  
8.59
-0.08 (-0.92%)
4:30:26 PM EDT: $8.59 0.00 (0.00%)
Products, Regulatory

Brazilian Health Regulatory Agency (Anvisa) Authorizes Sorrento Phase 2 Pivotal Clinical Trial Of Covi-Msc In Hospitalized Covid-19 Patients With Acute Respiratory Distress Syndrome

Published: 05/20/2021 13:26 GMT
Sorrento Therapeutics Inc (SRNE) - Brazilian Health Regulatory Agency (anvisa) Authorizes Sorrento Phase 2 Pivotal Clinical Trial of Covi-msc in Hospitalized Covid-19 Patients With Acute Respiratory Distress Syndrome.
Sorrento Therapeutics Inc - Anticipates Commencing Enrollment of Patients in Study in June 2021.
Sorrento Therapeutics Inc - Study Will Compare Therapy Using Mesenchymal Stem Cells to Placebo in 100 Covid-19 Patients Hospitalized Due to Ards.